Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.

PURPOSE Recent data from randomized clinical trials with oncolytic viral therapies and with cancer immunotherapies have finally recapitulated the promise these platforms demonstrated in preclinical models. Perhaps the greatest advance with oncolytic virotherapy has been the appreciation of the importance of activation of the immune response in therapeutic activity. Meanwhile, the understanding ...

Immune checkpoint blockade for GBM 1 Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, Keith L. Ligon, Scott J. Rodig, Shakti H. Ramkissoon, Kristen L. Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y. Wen, Annick D. Van Den Abbeele, F. Stephen Hodi, Lei Qin, Nancy E. Kohl, Arlene H. Sharpe, Glenn Dranoff , and Gordon J. Freeman Center for Neuro-Oncology, Department of Medical Oncology, Belfer Institute for Applied C...

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade

Oncolytic viruses (OVs) target and destroy cancer cells while sparing their normal counterparts. These viruses have been evaluated in numerous studies at both pre-clinical and clinical levels and the recent Food and Drug Administration (FDA) approval of an oncolytic herpesvirus-based treatment raises optimism that OVs will become a therapeutic option for cancer patients. However, to improve cli...

Corticosteroids and immune checkpoint blockade

checkpoint blockade to stimulate the immune response have demonstrated promising outcomes in advanced malignancies [1]. As a result, novel cancer immunotherapy was named a scientific breakthrough of the year in 2013 by Science. Consistent with its mechanism of action of de novo stimulation or enhancement of pre-existing T cell responses, a number of immune-related adverse events (irAEs) have be...